Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Infant Neuroblastoma Study (INES 99)
NCT00417053Phase 3Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 3, open-label trial of carboplatin, cyclophosphamide, doxorubicin, etoposide phosphate, vincristine and 2 more in neuroblastoma (5 arms), sponsored by Children's Cancer and Leukaemia Group. Primary endpoints: Overall Survival at 5 years and Morbidity. Status: unknown.
02
Drugs
carboplatincyclophosphamidedoxorubicinetoposide phosphatevincristine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00417053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417053.